Yes, you can take sitagliptin and digoxin together in most cases, but this combination requires careful monitoring because sitagliptin may increase digoxin levels in your bloodstream, raising the risk of digoxin toxicity. While the FDA labeling for sitagliptin does not list a major contraindication with digoxin, the pharmacological relationship between these drugs means your doctor and pharmacist need to watch your response closely and may adjust your digoxin dose.
The FDA-approved labeling for sitagliptin (Januvia) does not explicitly contraindicate concurrent use with digoxin, and no boxed warning exists for this pairing. However, the sitagliptin label does note that the drug is a substrate for renal excretion and may have drug interactions in patients with renal impairment. Digoxin is also renally cleared and has a narrow therapeutic window—meaning the difference between an effective dose and a toxic dose is small.
The digoxin label (FDA approved) lists numerous drugs that can increase digoxin serum concentrations, including medications that affect renal function or compete for renal tubular secretion. While sitagliptin is not explicitly named in the digoxin label's interaction section, the mechanistic pathway—renal competition and potential effects on organic cation transporters—warrants close attention.
The takeaway: This is not a "do not use" combination, but it is a "use with caution and monitor" combination. Your pharmacist should flag this pairing when filling your prescription, and your doctor should be aware if you are starting one while already taking the other.
To understand why sitagliptin and digoxin require monitoring together, you need to know how each drug moves through your body.
Sitagliptin's role: Sitagliptin is a DPP-4 inhibitor—a class of oral diabetes medication that lowers blood sugar by preventing the breakdown of incretin hormones. Sitagliptin is metabolized primarily by the kidneys and is a substrate for organic cation transporter 2 (OCT2) and a potential substrate for P-glycoprotein (P-gp), two important proteins that help clear drugs from your body via renal tubular secretion.
Digoxin's role: Digoxin is a cardiac glycoside used to treat heart failure and atrial fibrillation. It works by slowing the heart rate and increasing the force of heart contractions. Digoxin is also primarily cleared by the kidneys and is a substrate for P-glycoprotein and organic cation transporters. Critically, digoxin has a very narrow therapeutic window: blood levels between 0.5–2.0 nanograms per milliliter (ng/mL) are considered therapeutic, but levels above 2.0 ng/mL increase the risk of digoxin toxicity, which can cause dangerous arrhythmias and other serious side effects.
The interaction mechanism: When you take sitagliptin and digoxin together, sitagliptin may compete with digoxin for renal tubular secretion via the OCT2 and P-glycoprotein transporters. If sitagliptin occupies these transporters, digoxin clearance may slow, causing digoxin to accumulate in your bloodstream. Additionally, if you have any degree of renal impairment—which is common in older patients and those with diabetes—the competition for renal clearance becomes more pronounced. The result is a potential increase in digoxin serum concentrations, which elevates your risk of toxicity.
This is not a pharmacodynamic interaction (where two drugs have opposing effects on the same receptor). It is a pharmacokinetic interaction—sitagliptin changes how your body processes and removes digoxin.
Not everyone taking both drugs will experience a clinically significant interaction, but certain patient populations face higher risk:
Margaret is a 68-year-old woman with type 2 diabetes and atrial fibrillation. She has been stable on digoxin 0.25 mg once daily for three years, with a serum digoxin level of 1.2 ng/mL (in the therapeutic range). Her eGFR is 52 mL/min (stage 3a CKD), reflecting mild kidney disease. Her doctor prescribes sitagliptin 100 mg daily to improve her blood sugar control.
Three weeks after starting sitagliptin, Margaret develops new symptoms: she feels more fatigued than usual, notices occasional heart palpitations, and has mild nausea after meals. She assumes the nausea is from the sitagliptin and doesn't call her doctor.
These are red flags for digoxin toxicity. When her doctor ordered a digoxin level two weeks after starting sitagliptin (as part of routine monitoring), it came back at 2.8 ng/mL—above the therapeutic range and into the toxic range. The culprit: sitagliptin competitively inhibited digoxin's renal clearance, causing accumulation.
The management: Margaret's digoxin dose was reduced from 0.25 mg to 0.125 mg daily, and a repeat digoxin level one week later confirmed she was back in the therapeutic range. She was also advised to have her digoxin level checked every 6–12 months while on sitagliptin, and to stay well-hydrated and avoid NSAIDs (which can further reduce kidney function).
Robert is 72 years old with a 10-year history of heart failure and is taking digoxin 0.25 mg twice daily. His eGFR is 45 mL/min (stage 3b CKD), and his last digoxin level was 1.6 ng/mL, which is therapeutic. He is also taking verapamil for rate control in atrial fibrillation. Recently, his fasting glucose has been consistently between 140–180 mg/dL, and his doctor starts sitagliptin 100 mg once daily.
Robert's pharmacist reviews his medication list and immediately notes the triple interaction: sitagliptin + digoxin + verapamil. Verapamil is a P-glycoprotein inhibitor, so the combination of sitagliptin and verapamil competing for renal clearance while also inhibiting P-gp creates a high-risk scenario for digoxin accumulation.
The pharmacist calls Robert's doctor and recommends: (1) checking a baseline digoxin level before starting sitagliptin, (2) reducing the digoxin dose from 0.25 mg twice daily to 0.25 mg once daily, and (3) rechecking the digoxin level 5–7 days after the dose change. The doctor agrees. Robert's digoxin level drops to 1.1 ng/mL on the lower dose, still therapeutic, and he avoids toxicity. He continues on sitagliptin for glycemic control without incident because the dose adjustment was made proactively.
If you are already taking both medications:
If your doctor is considering starting one drug while you're on the other:
Contact your healthcare provider immediately (or go to the emergency room) if you experience any of these symptoms while taking sitagliptin and digoxin:
Call during business hours (rather than rushing to the ER) if you experience mild symptoms like decreased appetite, mild nausea, or slight fatigue, but do not wait more than a day to reach your doctor.
Sitagliptin and digoxin are just one example of drug pairs that require monitoring. If you are taking multiple medications—especially for diabetes, heart disease, or kidney disease—you may have other interactions you're not aware of. Sitagliptin and metformin interactions, digoxin and verapamil combinations, and sitagliptin and ACE inhibitors are all common real-world scenarios that warrant attention. Visit checkdruginteractions.com to enter your complete medication list and get a personalized interaction report. Our checker is powered by over 250,000 FDA drug labels and the NIH National Library of Medicine, giving you the most comprehensive and current interaction data available. Don't wait for your next doctor's visit—check your medications today and share the results with your pharmacist or doctor.
CDI checks every pair across up to 20 drugs — backed by FDA and NIH data.
Drug interaction data sourced from U.S. FDA drug labeling via openFDA and the U.S. National Library of Medicine (NLM), National Institutes of Health. For informational purposes only. Always consult your pharmacist or physician before making any medication decisions.
Methotrexate and ibuprofen have a major FDA-documented interaction. Learn mechanism, monitoring, and safe management strategies for healt...
Tacrolimus and fluconazole interaction explained. Learn severity, risks, and what FDA labels say about combining these drugs.
Is it safe to take methimazole and warfarin together? Learn about this drug interaction from FDA data and pharmacology.